3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To examine predictors of remission among patients with psoriatic arthritis (PsA) initiating a tumor necrosis factor (TNF) inhibitor.

          Related collections

          Author and article information

          Journal
          J. Rheumatol.
          The Journal of rheumatology
          The Journal of Rheumatology
          0315-162X
          0315-162X
          May 2019
          : 46
          : 5
          Affiliations
          [1 ] From the University of Pennsylvania, Philadelphia, Pennsylvania; Corrona Research Foundation; New York University Hospital for Joint Diseases, New York, New York; University of Alabama at Birmingham, Birmingham, Alabama; University of Massachusetts, Worcester; Brigham and Women's Hospital, Boston, Massachusetts; University of California San Diego, San Diego, California; Albany Medical College, Albany, New York; Swedish Medical Center; University of Washington, Seattle, Washington, USA. alexis.ogdie@uphs.upenn.edu.
          [2 ] A. Ogdie, MD, MSCE, University of Pennsylvania; J.L. Palmer, PhD, Corrona Research Foundation; J. Greenberg, MD, New York University Hospital for Joint Diseases; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham; L.R. Harrold, MD, MPH, Corrona Research Foundation; D.H. Solomon, MD, MPH, Brigham and Women's Hospital; A. Kavanaugh, MD, University of California at San Diego; J.M. Kremer, MD, Corrona Research Foundation, and Albany Medical College; P.J. Mease, MD, Swedish Medical Center, and University of Washington. alexis.ogdie@uphs.upenn.edu.
          [3 ] From the University of Pennsylvania, Philadelphia, Pennsylvania; Corrona Research Foundation; New York University Hospital for Joint Diseases, New York, New York; University of Alabama at Birmingham, Birmingham, Alabama; University of Massachusetts, Worcester; Brigham and Women's Hospital, Boston, Massachusetts; University of California San Diego, San Diego, California; Albany Medical College, Albany, New York; Swedish Medical Center; University of Washington, Seattle, Washington, USA.
          [4 ] A. Ogdie, MD, MSCE, University of Pennsylvania; J.L. Palmer, PhD, Corrona Research Foundation; J. Greenberg, MD, New York University Hospital for Joint Diseases; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham; L.R. Harrold, MD, MPH, Corrona Research Foundation; D.H. Solomon, MD, MPH, Brigham and Women's Hospital; A. Kavanaugh, MD, University of California at San Diego; J.M. Kremer, MD, Corrona Research Foundation, and Albany Medical College; P.J. Mease, MD, Swedish Medical Center, and University of Washington.
          Article
          jrheum.171034
          10.3899/jrheum.171034
          30647182
          0b6c46ec-1033-47ca-893c-bf95787f185c
          History

          EPIDEMIOLOGY,PSORIATIC ARTHRITIS,TNF INHIBITORS,THERAPY RESPONSE,OUTCOMES

          Comments

          Comment on this article